PPP4R1-AS1: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Target Name: PPP4R1-AS1

NCBI ID: G101927323

PPP4R1-AS1

Other Name(s): PPP4R1 antisense RNA 1 | PPP4R1 antisense RNA 1, transcript variant 1 | PPP4R1-AS1 variant 1

PPP4R1-AS1: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and their respective neurotransmitters, leading to the decline in cognitive and motor functions. These diseases have a significant impact on the quality of life and often result in significant disability. The underlying causes of neurodegenerative diseases are still not fully understood, but it is known that they are associated with inflammation and oxidative stress. Therefore, there is a growing interest in developing new treatments for these diseases that target inflammation and oxidative stress.

PPP4R1-AS1: A Potential Drug Target and Biomarker

The protein PPP4R1 (Protamineptide Peptidase 4, Regulatory Subunit 1) is a key enzyme in the urea cycle, which is a process that removes excess ammonia from the urine of humans and other organisms. PPP4R1 plays a crucial role in the regulation of the urea cycle and its activity is regulated by several factors, including intracellular signaling pathways. One of the well-known signaling pathways involving PPP4R1 is the TOR signaling pathway. TOR (Triacyclic Tetraethylamine) is a highly potent inhibitor of the DNA-protein binding, and it is known to play a crucial role in the regulation of cell growth, metabolism, and stress responses.

Recent studies have identified PPP4R1 as a potential drug target for neurodegenerative diseases. By inhibiting the activity of PPP4R1, it is possible to reduce the production of ammonia, which is a hallmark of neurodegenerative diseases, and potentially slow down or even reverse the degenerative process.

In addition to its potential therapeutic applications, PPP4R1 has also been identified as a potential biomarker for neurodegenerative diseases. The urinary excretion of PPP4R1 has been shown to be reduced in individuals with neurodegenerative diseases compared to healthy individuals. Furthermore, individuals with neurodegenerative diseases have increased levels of PPP4R1 in their urine compared to healthy individuals. These findings suggest that PPP4R1 may serve as a diagnostic biomarker for neurodegenerative diseases and could potentially be used as a target for new therapeutic approaches.

Targeting PPP4R1: A Promising Approach

PPP4R1 is a well-established enzyme that is involved in various cellular processes, including DNA repair, metabolism, and stress responses. Therefore, targeting PPP4R1 directly is not an easy task. However, several approaches have been proposed to inhibit PPP4R1 activity and potentially slow down or reverse the degenerative process.

One approach is to use small molecules as inhibitors of PPP4R1. This approach has been used to inhibit the activity of various enzymes, including PPP4R1, and has shown promise in targeting neurodegenerative diseases. For example, a small molecule called 4-fluoro-2-methylphenyl-1-butanone (4-F-MBP) has been shown to inhibit the activity of PPP4R1 and has been shown to protect against neurodegenerative diseases in animal models.

Another approach is to use antibodies to target PPP4R1 directly. This approach has been used to treat various diseases, including neurodegenerative diseases. For example, antibodies against PPP4R1 have been shown to cross-react with

Protein Name: PPP4R1 Antisense RNA 1

The "PPP4R1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP4R1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets